x
health care-associated infections; Acinetobacter spp.; beta-lactams; multiresistance; biofilm; blaOXA-5
Acinetobacter spp. are coccobacillary bacteria, Gram-negatives, aerobics, nonfermenting, ubiquitous that stand out for being opportunistic pathogens in hospitalized patients due to their great capacity to develop on abiotic surfaces, to resist desiccation and to be resistant to the action of multiple antibiotics. Of this genus, Acinetobacter baumannii stands out, which in 2017 was classified by the World Health Organization as a critical priority for multidrug resistance, thus representing one of the greatest threats to human life. Resistance to beta-lactams has been reported in association with resistance genes that, with each passing day, increase and are spread inter and intraspecies. Therefore, this work aims to identify and characterize the different species of Acinetobacter spp. isolated from clinical samples of patients, health workers and hospital structures of intensive care units of hospitals in the Porto Velho region, as well as their phenotypic and molecular profiles of resistance to beta-lactams. 201 Acinetobacter spp. isolates were identified, with Acinetobacter baumannii being the most incident species among the nine identified. The isolates are more sensitive to the action of polymyxin B, however there was greater resistance to the classes of monobactam, cephalosporins and fluroquinolones, determining a scenario that 53.3% of the isolates were classified as multiresistant, of which 77.7% can be extensively resistant. In vitro, non-betalactam antibiotics had 21.08% more chances of being more effective. 83% of the isolates were negative for extended sputum beta-lactamases, a condition statistically associated with multiresistant isolates. 90.6% of the isolates were biofilm producers, especially those from patients. The blaOXA-23 gene was the most amplified betalactamase in the isolates, followed by the oxacilinases blaOXA-24 and blaOXA-58. blaNDM was the most amplified metallobetalactamase gene, and 92.86% of these genes were identified as coexisting with other betalactamase genes. It is concluded that surveillance should be continuous, suggesting new studies aiming at identifying other genes encoding beta-lactamases and or other inactivating enzymes for antibiotic drugs, as well genes that induce the production of efflux pumps, the modification of membrane permeability or porins channels.